Deep Breath Intelligence

Executive Summary

Deep Breath Intelligence (DBI) is a Swiss MedTech company pioneering non-invasive breath analysis for early disease detection and health optimization. Founded in 2018 in Zurich, DBI combines high-resolution mass spectrometry with advanced machine learning to decode metabolomic signatures in exhaled breath. The company offers a suite of hardware, software, and contract research services, positioning itself as a platform for breath-based diagnostics across oncology, respiratory diseases, and metabolic conditions. DBI's technology aims to replace invasive biopsies and blood tests with a simple, rapid breath test, potentially reducing healthcare costs and improving patient outcomes. DBI operates in the rapidly growing breath diagnostics market, projected to reach $5 billion by 2030. While still early-stage, the company has demonstrated proof-of-concept in multiple disease areas. Key upcoming milestones include the completion of a pivotal clinical study for lung cancer detection and progression towards CE marking for its first diagnostic panel. With a lean team and a focus on rigorous validation, DBI is well-positioned to capture partnerships with pharmaceutical companies and healthcare providers. The combination of a non-invasive approach and AI-powered data analysis gives DBI a competitive edge in the emerging field of precision breath medicine.

Upcoming Catalysts (preview)

• Q3 2026Pivotal clinical study results for lung cancer breath test70% success
• Q2 2027CE marking approval for initial diagnostic panel80% success
• Q4 2026Strategic partnership with top-10 pharma for chronic obstructive pulmonary disease (COPD) biomarker validation60% success